Fate Therapeutics, a US-based drugs company, has raised $9.2m from 17 investors, according to a regulatory filing first seen by news provider Fierce Biotech.
In May last year, Japan-based drugs company Takeda Pharmaceutical’s corporate venturing unit made an equity investment of undisclosed size in Fate Therapeutics as part of a plan to help its parent move into regenerative medicines.
Takeda Ventures joined peers Astellas Venture Management, Genzyme Ventures and a third, unnamed corporate venturing group as strategic investor in Fate.
The venture capital firms backing Fate are Arch Venture Partners, OVP Venture Partners, Polaris Venture Partners and Venrock.
Founded in 2007, Fate had previously raised $15m in its series A round in 2008 and $30m in its series B round in November 2009. Its regulatory filing for the latest round shows Fate’s directors include Mark Enyedy Chief Executive Proteostasis Therapeutics and former president of the transplant, oncology and multiple sclerosis divisions at Genzyme, and Biogen Idec’s former chairman William Rastetter and a partner at Venrock.